Clinical overview on Lipoplatin^™: a successful liposomal formulation of cisplatin

Bibliography

• Boulikas T, Pantos A, Bellis E, Christofis P. Designing platinum compounds in cancer: structures and mechanisms [review]. Cancer Therapy 2007;5:537-83. Available from: www.cancer-therapy.org
   Google Scholar
• Boulikas T, Tsogas I. Microtubule-targeted antitumor drugs: chemistry, mechanisms and nanoparticle formulations. Gene Ther Mol Biol 2008;1:343-87. Available from: www.gtmb.org
   Google Scholar
• Ribatti D. The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des 2009;15:345-52
   PubMed Web of Science ®Google Scholar
• Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009;8:567-72
   PubMed Web of Science ®Google Scholar
• Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-32
   PubMed Web of Science ®Google Scholar
• Al-Janadi A, Chandana SR, Conley BA. Histone deacetylation: an attractive target for cancer therapy? Drugs R D 2008;9:369-83
   PubMedGoogle Scholar
• Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications [review]. Int J Oncol 2008;33:637-46
   PubMed Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26:3785-90
   PubMed Web of Science ®Google Scholar
• Sakamoto-Hojo ET, Balajee AS. Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment. Anticancer Agents Med Chem 2008;8:402-16
   PubMed Web of Science ®Google Scholar
• Abreu PA, Dellamora-Ortiz G, Leão-Ferreira LR, et al. DNA methylation: a promising target for the twenty-first century. Expert Opin Ther Targets 2008;12:1035-47
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13
   PubMed Web of Science ®Google Scholar
• Boulikas T. Status of gene therapy in 1997: molecular mechanisms, disease targets, and clinical applications. Gene Ther Mol Biol 1998;1:1-172
   Google Scholar
• Bachtarzi H, Stevenson M, Fisher K. Cancer gene therapy with targeted adenoviruses. Expert Opin Drug Deliv 2008;5:1231-40
   PubMed Web of Science ®Google Scholar
• Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004;12:3-12
   PubMed Web of Science ®Google Scholar
• Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969;222:385-6
   PubMed Web of Science ®Google Scholar
• Sorenson C, Eastman A. Mechanism of cis-diamminedichloroplatinum (11)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8
   PubMed Web of Science ®Google Scholar
• Garcia-del-Muro X, Maroto P, Gumà J, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008;26:5416-21
   PubMed Web of Science ®Google Scholar
• Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Therapy 2003;1:47-61
   PubMedGoogle Scholar
• Harmers FP, Gispen WH, Neijt JP. Neurotoxic side-effects of cisplatin. Eur J Cancer 1991;27:372-6
   PubMed Web of Science ®Google Scholar
• Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann NY Acad Sci 1999;884:15-18
   PubMed Web of Science ®Google Scholar
• Kitada N, Takara K, Minegaki T, et al. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol 2008;62:577-84
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep 2005;13:589-95
   PubMed Web of Science ®Google Scholar
• Gabizon A, Tzemach D, Mak L, et al. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002;10:539-48
   PubMed Web of Science ®Google Scholar
• Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991;1070:187-92
   PubMed Web of Science ®Google Scholar
• Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-6
   PubMed Web of Science ®Google Scholar
• Huang SK, Martin FJ, Jay G, et al. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993;143:10-4
   PubMed Web of Science ®Google Scholar
• Martin F, Boulikas T. The challenge of liposomes in gene therapy. Gene Ther Mol Biol 1998;1:173-214
   Google Scholar
• Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6
   PubMed Web of Science ®Google Scholar
• Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005;25:3031-40
   PubMed Web of Science ®Google Scholar
• Boulikas T. Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin™. Lipoplatin™ as a chemotherapy and antiangiogenesis drug. Cancer Ther 2007;5:351-76
   Google Scholar
• Veal GJ, Griffin MJ, Price E, et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 2001;84:1029-35
   PubMed Web of Science ®Google Scholar
• White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006;95:822-8
   PubMed Web of Science ®Google Scholar
• Meerum Terwogt JM, Groenewegen G, Pluim D, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002;49:201-10
   PubMed Web of Science ®Google Scholar
• Vokes EE, Gordon GS, Mauer AM, et al. A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clin Lung Cancer 2000;2:128-32
   PubMedGoogle Scholar
• Kim ES, Lu C, Khuri FR, et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001;34:427-32
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Yom SS, Liu L, et al. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs 2002;20:343-9
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001;12:493-6
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Tanaka T, Kurokawa H, et al. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Anticancer Res 2007;27:2209-16
   PubMed Web of Science ®Google Scholar
• Song IS, Savaraj N, Siddik ZH, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004;3:1543-9. Erratum in: Mol Cancer Ther 2005;4:864
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-86
   PubMed Web of Science ®Google Scholar
• Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, et al. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 2006;29:225-35
   PubMed Web of Science ®Google Scholar
• Safaei R, Larson BJ, Cheng TC, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005;4:1595-604
   PubMed Web of Science ®Google Scholar
• Rabik CA, Maryon EB, Kasza K, et al. Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 2009;64:133-42
   PubMed Web of Science ®Google Scholar
• Zisowsky J, Koegel S, Leyers S, et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007;73:298-307
   PubMed Web of Science ®Google Scholar
• Owatari S, Akune S, Komatsu M, et al. Copper-transporting P-Type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 2007;67:4860-8
   PubMed Web of Science ®Google Scholar
• Choi MK, Kim DD. Platinum transporters and drug resistance. Arch Pharm Res 2006;29:1067-73
   PubMed Web of Science ®Google Scholar
• Negoro K, Yamano Y, Nakashima D, et al. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line. Oncol Rep 2009;21:443-9
   PubMed Web of Science ®Google Scholar
• Yokoo S, Masuda S, Yonezawa A, et al. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos 2008;36:2299-306
   PubMed Web of Science ®Google Scholar
• Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66:8847-57
   PubMed Web of Science ®Google Scholar
• Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008;7:3247-55
   PubMed Web of Science ®Google Scholar
• Acehan D, Jiang X, Morgan DG, et al. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 2002;9:423-32
   PubMed Web of Science ®Google Scholar
• Wei Q, Dong G, Franklin J, Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 2007;72:53-62
   PubMed Web of Science ®Google Scholar
• Zhu J, Yang Y, Wu J. Bcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis. Cell Res 2007;17:441-8
   PubMed Web of Science ®Google Scholar
• Villedieu M, Briand M, Duval M, et al. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21(WAF1/CIP1), Bcl-2 and Bcl-x(L) expression. Gynecol Oncol 2007;105:373-84
   PubMed Web of Science ®Google Scholar
• Nehmé A, Baskaran R, Aebi S, et al. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 1997;57:3253-7
   PubMed Web of Science ®Google Scholar
• Han Z, Hong L, Wu K, et al. Reversal of multidrug resistance of gastric cancer cells by downregulation of Akt1 with Akt1 siRNA. J Exp Clin Cancer Res 2006;25:601-6
   PubMed Web of Science ®Google Scholar
• Villar J, Quadri HS, Song I, et al. PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cancer Res 2009;69:102-10
   PubMed Web of Science ®Google Scholar
• Devarajan P, Tarabishi R, Mishra J, et al. Low renal toxicity of Lipoplatin compared to cisplatin in animals. Anticancer Res 2004;24:2193-200
   PubMed Web of Science ®Google Scholar
• Marr AK, Kurzman ID, Vail DM. Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs. Am J Vet Res 2004;65:1474-8
   PubMed Web of Science ®Google Scholar
• Fedier A, Poyet C, Perucchini D, et al. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal. Anticancer Drugs 2006;17:315-23
   PubMed Web of Science ®Google Scholar
• Fedier A, Erdmann R, Boulikas T, Fink D. Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner. Int J Oncol 2006;29:1303-10
   PubMed Web of Science ®Google Scholar
• Arienti C, Tesei A, Ravaioli A, et al. Activity of lipoplatin in tumor and in normal cells in vitro. Anticancer Drugs 2008;19:983-90
   PubMed Web of Science ®Google Scholar
• Froudarakis ME, Pataka A, Pappas P, et al. Phase 1 trial of Lipoplatin and gemcitabine as a second-line chemotherapy in patients with non-small cell lung carcinoma. Cancer 2008;113:2752-60
   PubMed Web of Science ®Google Scholar
• Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME. Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with Lipoplatin and gemcitabine. Oncology 2007;73(5-6):426-9
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Boulikas T, Rigatos SK, et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced cancer patients. Phase I-II study. Ann Oncol 2002;13:25
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Androulakis N, Souglakos J, et al. Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res 2008;28:1303-8
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Boulikas T, Vougiouka M, et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 2006;15:1201-4
   PubMed Web of Science ®Google Scholar
• Available from: http://www.emea. europa.eu/pdfs/human/comp/opinion/16785007en.pdf
   Google Scholar
• Mylonakis N, Athanasiou A, Ziras N, et al. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as 1st line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer (NSCLC). Lung Cancer 2009 [In Press]
   Google Scholar
• Farhat FS, Nasser A, Ibrahim K, et al. Preliminary results of a phase II study of Lipoplatin (Liposomal Cisplatin) – Vinorelbine combination as first line treatment in HER2/neu negative advanced breast cancer [abstract # 550699]. 31st Annual San Antonio Breast Cancer Symposium: 2008
   Google Scholar
• Anevlavis S, Pataka A, Kouliatsis G, et al. A phase II trial of Lipoplatin-gemcitabine in patients with advanced NSCLC: preliminary results. Eur Respir J 2008;32:762s
   Google Scholar
• Koukourakis MI, Giatromanolaki A, Pitakoudis M, et al. Concurrent liposomal cisplatin (Lipoplatin™), 5-Fluorouracil and?T. Concurrent liposomal cisplatin (Lipoplatin Radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Submitted
   Google Scholar
• Skarlatos J, Kosma L, Koukourakis M, et al. Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. Int J Colorectal Dis 1996;11:206-10
   PubMed Web of Science ®Google Scholar
• Boulikas T, Mylonakis N, Sarikos G, et al. Superiority of Lipoplatin™ plus gemcitabine compared to cisplatin plus gemcitabine as first-line treatment against NSCLC: Preliminary results of a randomized, multicenter phase III trial. ASCO Abstract ID: 33204 (1-5 June 2007, Chicago, Illinois, USA)
   Google Scholar
• Kosmas C, Angel J, Athanasiou A, et al. Interim Phase III analysis of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC. Abstract number: E15-1858. Submitted to ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, 20-24 Sept 2009
   Google Scholar
• Kim SW, Suh C, Lee SD, et al. Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003;41:221-6
   PubMed Web of Science ®Google Scholar
• Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 2004;9(Suppl 2):16-23
   PubMed Web of Science ®Google Scholar
• Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125-37
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Michalopoulou P, Antoniou D, et al. Liposomal cisplatin and paclitaxel versus cisplatin and paclitaxel in advanced NSCLC. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25:7684
   Google Scholar
• Stathopoulos GP, Antoniou D, Dimitroulis J, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer. Submitted
   Google Scholar
• Jehn CF, Boulikas T, Kourvetaris A, et al. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 2007;27:471-5
   PubMed Web of Science ®Google Scholar
• Jehn CF, Boulikas T, Kourvetaris A, et al. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 2008;28:3961-4
   PubMed Web of Science ®Google Scholar
• Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007;45:21-4
   PubMed Web of Science ®Google Scholar
• Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997;15:297-303
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
   PubMed Web of Science ®Google Scholar
• Gao G, Jiang J, Liang X, et al. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009 In Press
   Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
   PubMed Web of Science ®Google Scholar
• Tassinari D, Carloni F, Santelmo C, et al. Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. Rev Recent Clin Trials 2009;4(1):27-33
   PubMedGoogle Scholar
• Kosmas C, Tsavaris N, Syrigos K, et al. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol 2007;59:51-9
   PubMed Web of Science ®Google Scholar
• Felip E, Rosell R. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 2008;4:579-85
   PubMedGoogle Scholar
• Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-87
   PubMed Web of Science ®Google Scholar
• Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006;44:1173-83
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, McCormack B, Obrenovic M, et al. Vaccine entrapment in liposomes. Methods 1999;19:156-62
   PubMed Web of Science ®Google Scholar
• Soni PN, Brown D, Saffie R, et al. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology 1998;28:1402-10
   PubMed Web of Science ®Google Scholar
• Zhang L, Granick S. How to stabilize phospholipid liposomes (using nanoparticles). Nano Lett 2006;6:694-8
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006;66:3271-7
   PubMed Web of Science ®Google Scholar
• Martin F, Boulikas T. The challenge of liposomes in gene therapy. Gene Ther Mol Biol 1998;1:173-214
   Google Scholar
• Gregoriadis G, Fernandes A, Mital M, McCormack B. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell Mol Life Sci 2000;57:1964-9
   PubMed Web of Science ®Google Scholar
• Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci 2006;95:1114-26
   PubMed Web of Science ®Google Scholar
• Li YY, Qian GS, Huang GJ, et al. Enhancement of antiangiogenic effects of human canstatin with a hypoxia-regulated transgene vector in lung cancer model. Cancer J 2006;12:136-46
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang XW, Wang GQ, et al. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. Cancer Gene Ther 2006;13(10):940-7
   Web of Science ®Google Scholar
• Liang S, Lin T, Ding J, et al. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med 2006;84:764-73
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos I. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res 2006;26:1489-94
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, et al. A Phase I study of the liposomal Semliki Forest virus expressing the human IL-12 gene in cancer patients. In preparation
   Google Scholar
• Ravaioli A, Papi M, Pasquini E, et al. Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother 2009;21:86-90
   PubMed Web of Science ®Google Scholar
• Ranson M, Thatcher N. Paclitaxel: a hope for advanced non-small cell lung cancer? Expert Opin Investig Drugs 1999;8:837-48
   PubMedGoogle Scholar
• Lazarioti F, Boulikas T. Diagnostic and Therapeutic Efficacy of Imaging Modalities in Non-Small Cell Lung Cancer (NSCLC): experience from a Phase III clinical study using tumor targeted Lipoplatin nanoparticles. Cancer Ther 2008;6:629-46. Available from: www.cancer-therapy.org
   Google Scholar